AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAlloSource
About this trial
This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Eligibility criteria
Qualifiers
Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;
Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;
Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.
Disqualifiers
Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction
Did not have post-operative evaluations at the clinical site.
Trial design
Treatments tested in this trial
- AlloMend® Acellular Dermal Matrix allograft
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov